Core Viewpoint - The article reflects optimism regarding Rigel Pharmaceuticals' performance, particularly in relation to the growth of their products and clinical trials [1]. Group 1: Company Performance - Rigel Pharmaceuticals has shown promising growth, which is highlighted as a key factor for potential investment opportunities [1]. Group 2: Industry Insights - The article emphasizes the importance of understanding the science behind biotech investments, suggesting that thorough analysis of clinical trials is crucial for making informed decisions in this sector [1].

分组1 - Rigel Pharmaceuticals reported quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.33 per share, but showing an increase from $0.8 per share a year ago, resulting in an earnings surprise of -14.29% [1] - The company posted revenues of $69.8 million for the quarter ended December 2025, which aligns with the Zacks Consensus Estimate and represents a year-over-year increase from $57.6 million [2] - Rigel has surpassed consensus EPS estimates three times over the last four quarters, indicating a generally positive trend in earnings performance [2] 分组2 - The stock has underperformed the market, losing about 19.2% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is $0.90 on revenues of $61.67 million, and for the current fiscal year, it is $3.97 on revenues of $285.45 million [7] - The Medical - Drugs industry, to which Rigel belongs, is currently in the bottom 45% of the Zacks industry rankings, suggesting potential challenges ahead [8]

Core Insights - Rigel Pharmaceuticals reported a significant increase in net product sales for 2025, reaching $232 million, which is a 60% increase compared to 2024, driven by increased demand and favorable dynamics in patient affordability [1][6][20] - The company has transitioned from a single-product focus to marketing three products: TAVALISSE, REZLIDHIA, and GAVRETO, with plans to pursue late-stage in-licensing and acquisition opportunities [2][3][20] - Rigel's financial performance was bolstered by a non-cash deferred tax benefit, resulting in a net income of $367 million for 2025, compared to $17.5 million in 2024 [4][19][24] Financial Performance - For Q4 2025, Rigel reported total revenue of $69.8 million, including $65.4 million in net product sales and $4.4 million in collaboration revenues [16] - The company guided for 2026 revenue between $275 million and $290 million, with expectations of positive net income while funding clinical development programs [20][21] - Total costs and expenses for 2025 were $168.8 million, an increase from $155.1 million in 2024, with R&D costs rising due to clinical activities for R289 and olutasidenib [17][24] Product Performance - TAVALISSE generated $45.6 million in sales for Q4 2025, up 47% year-over-year, while GAVRETO and REZLIDHIA contributed $10.2 million and $9.6 million, respectively [9][6] - R289, the lead pipeline candidate, showed early efficacy in lower-risk myelodysplastic syndromes (MDS), with 33% of evaluable patients achieving transfusion independence [5][13][10] - The company is advancing R289 through a randomized dose-expansion study, with expectations for Phase 2 dose decision data by the end of the year [14][15] Strategic Outlook - Rigel aims to build on the momentum of its marketed products while selectively pursuing late-stage business development opportunities in hematology and oncology [2][21] - The company is focusing on NDA-ready or under-review assets that could be launched within the next three years [21] - Rigel's strategy includes leveraging partnerships for international product availability and regulatory submissions in new markets [8]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported net product sales of $65.4 million, a 41% increase year-over-year, with TAVALISSE generating $45.6 million, a 47% increase, GAVRETO at $10.2 million, a 27% increase, and REZLIDHIA at $9.6 million, a 29% increase [12][15][32] - Full year 2025 net product sales reached $232 million, an increase of $87 million or 60% compared to 2024, driven by increased demand and favorable gross to net dynamics [13][38] - The company reported net income of $268.1 million for Q4 2025, compared to $14.3 million for the same period in 2024, and a full year net income of $367 million, compared to $17.5 million in 2024 [35][38] Business Line Data and Key Metrics Changes - TAVALISSE, the cornerstone product, achieved record quarterly sales of $45.6 million, while GAVRETO and REZLIDHIA contributed $10.2 million and $9.6 million respectively [15][32] - The company has expanded its portfolio from a single product in 2020 to three commercial products by the end of 2025, indicating significant growth in its business lines [6][7] Market Data and Key Metrics Changes - The company anticipates a compound annual growth rate of approximately 35% in net product sales from 2022 to 2026, with guidance for 2026 net product sales between $255 million and $265 million [9][38] - The market for TAVALISSE is estimated to have over 14,000 patients in the second-line and later setting, indicating a substantial opportunity for growth [46] Company Strategy and Development Direction - The company’s strategy focuses on four core objectives: growing the commercial business, expanding the portfolio through in-licensing or acquisition, advancing the clinical development pipeline, and maintaining financial discipline [5][9] - The company plans to continue advancing R289 in lower risk MDS and explore additional indications, which are seen as large commercial opportunities [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential of R289 and the overall commercial portfolio, highlighting the importance of maintaining momentum from 2025 into 2026 [40] - The company acknowledged the challenges of sustaining high growth rates but remains committed to achieving double-digit growth in 2026 [70][71] Other Important Information - The company has a strong cash position, ending 2025 with cash equivalents and short-term investments of $155 million, up from $77.3 million at the end of 2024 [38] - The company has received Fast Track designation and Orphan Drug Designation for R289 from the FDA, indicating regulatory support for its development [23] Q&A Session Summary Question: What are the growth drivers for TAVALISSE and GAVRETO? - Management noted that TAVALISSE's growth was aided by a one-time favorable effect from increased patient affordability, and future growth will focus on new patient starts [44][46] Question: What is the rationale for exploring R289 in earlier line populations? - Management indicated that moving R289 into earlier lines of therapy could yield better activity compared to existing treatments, which have limitations [59][61] Question: How is enrollment in the R289 dose expansion phase progressing? - Management confirmed that enrollment is on track and that follow-up for evaluating red cell transfusion independence will require at least 16 weeks of treatment [67]

Financial Data and Key Metrics Changes - For Q4 2025, Rigel reported net product sales of $65.4 million, a 41% increase year-over-year, with TAVALISSE contributing $45.6 million (up 47%), GAVRETO at $10.2 million (up 27%), and REZLIDHIA at $9.6 million (up 29%) [32][35][36] - Full year 2025 net product sales reached $232 million, an increase of $87 million or 60% compared to 2024, driven by increased demand and favorable gross to net dynamics [12][13][37] - The company reported net income of $367 million for the full year 2025, compared to $17.5 million in 2024, reflecting a significant improvement in profitability [35][36] Business Line Data and Key Metrics Changes - TAVALISSE, the cornerstone product, achieved record quarterly sales of $45.6 million in Q4 2025, marking a 47% increase from Q4 2024 [15][32] - GAVRETO, launched in mid-2024, generated $10.2 million in Q4 2025, showing a 27% increase year-over-year, indicating successful integration into Rigel's portfolio [15][16] - REZLIDHIA, since its in-licensing in 2022, has grown to nearly $10 million in quarterly sales, with Q4 2025 sales of $9.6 million, a 29% increase compared to the prior year [16][18] Market Data and Key Metrics Changes - Rigel's net product sales growth reflects strong commercial execution and successful portfolio expansion, achieving a compound annual growth rate of approximately 35% since 2022 [9] - The company is expanding access to TAVALISSE in global markets, with ongoing regulatory approvals in various countries [17] Company Strategy and Development Direction - Rigel's growth strategy focuses on four core objectives: growing the commercial business, expanding the portfolio through in-licensing or acquisition, advancing the clinical development pipeline, and maintaining financial discipline [5][9] - The company aims to build on the commercial momentum of its three products while pursuing late-stage in-licensing opportunities and advancing R289 in lower risk MDS [9][10] - R289, a dual IRAK1 and IRAK4 inhibitor, is positioned as a potential treatment for lower risk MDS, with promising preliminary efficacy data [8][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, highlighting the transformational growth since 2020 and the expectation of continued double-digit growth in 2026 [39] - The company anticipates total revenue in the range of $275 million to $290 million for 2026, with a focus on maintaining profitability while funding clinical development programs [37][39] Other Important Information - Rigel has a proven track record in business development, successfully integrating acquired products into its portfolio with limited integration costs [10] - The company has received Fast Track and Orphan Drug Designation for R289 from the FDA, indicating a favorable regulatory pathway [23] Q&A Session Summary Question: What are the growth drivers for TAVALISSE and GAVRETO? - Management noted that TAVALISSE's growth was aided by a one-time favorable effect from increased patient affordability, and future growth will focus on new patient starts [41][44] - For GAVRETO, management highlighted targeted efforts to continue growth, leveraging the product's established presence in the market [46] Question: What is the rationale for exploring R289 in earlier line populations? - Management explained that moving R289 into earlier lines of therapy could yield better activity compared to existing treatments, which have shown limited response rates [58][61] Question: What is the status of enrollment for R289's dose expansion phase? - Enrollment is progressing well, with plans to select the recommended phase II dose in the second half of the year [66] Question: Why is the 2026 net product sales guidance conservative? - Management indicated that while they expect double-digit growth, the absence of one-time favorable effects from the previous year and the higher sales base present challenges [67][70] Question: Are there plans to expand the sales force? - Management stated that they are not looking to expand the sales organization at this time but are focused on maximizing the effectiveness of the current team [75][77]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported net product sales of $65.4 million, a 41% increase year-over-year, with TAVALISSE generating $45.6 million (up 47%), GAVRETO at $10.2 million (up 27%), and REZLIDHIA at $9.6 million (up 29%) [30][12][14] - Full year 2025 net product sales reached $232 million, an increase of $87 million or 60% compared to 2024, driven by increased demand and favorable gross to net dynamics [12][30] - The company reported net income of $268.1 million for Q4 2025, compared to $14.3 million for the same period in 2024, and a full year net income of $367 million, up from $17.5 million in 2024 [33][34] Business Line Data and Key Metrics Changes - TAVALISSE, the cornerstone product, achieved record quarterly sales of $45.6 million, while GAVRETO and REZLIDHIA contributed $10.2 million and $9.6 million respectively [13][14] - The company has expanded its portfolio from a single product in 2020 to three commercial products by the end of 2025, indicating successful portfolio growth [5][6] Market Data and Key Metrics Changes - The company has seen strong net product sales growth since emerging from the COVID pandemic, with a compound annual growth rate of approximately 35% since 2022 [8] - The market for TAVALISSE includes over 14,000 patients in the second-line and later setting, indicating significant growth potential [44] Company Strategy and Development Direction - The company’s strategy focuses on four core objectives: growing the commercial business, expanding the portfolio through in-licensing or acquisition, advancing the clinical development pipeline, and maintaining financial discipline [4][7] - The company plans to continue advancing R289 in lower risk MDS and explore additional indications, which represent large commercial opportunities [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, expecting total revenue in 2026 to be in the range of $275 million to $290 million, with net product sales guidance of $255 million to $265 million [35] - The company aims to maintain profitability while funding existing and new clinical development programs, reflecting a strong financial position [36][37] Other Important Information - The company has a promising clinical profile for R289, which has received Fast Track and Orphan Drug Designation from the FDA, indicating a favorable regulatory pathway [22] - The company is actively pursuing late-stage assets that are NDA-ready or already commercially available to enhance its portfolio [10] Q&A Session Summary Question: What are the growth drivers for TAVALISSE and GAVRETO? - Management noted that TAVALISSE's growth was aided by a one-time favorable effect from increased patient affordability, and future growth will focus on new patient starts [42][44] - For GAVRETO, management highlighted targeted efforts to continue growth, leveraging the full year of sales compared to the previous year [45] Question: What is the rationale for exploring R289 in earlier line populations? - Management explained that moving R289 into earlier lines of therapy could yield better activity compared to the heavily pretreated population currently being studied [58] Question: What are the challenges in patient enrollment for R289? - Management confirmed that enrollment is progressing well and that patients need to be treated for at least 16 weeks to evaluate red cell transfusion independence [66] Question: Why is the 2026 sales guidance conservative? - Management indicated that while they expect double-digit growth, the absence of one-time favorable effects from the previous year and the higher sales base make it a challenging outlook [67][70] Question: Are there plans to expand the sales force? - Management stated that they are not looking to expand the sales organization at this time but are focused on maximizing the impact of the current team [78]

Q4 & FY 2025 Financial Results Presentation March 3, 2026 1 Forward Looking Statements Rigel Participants Raul Rodriguez President & Chief Executive Officer Ray Furey, J.D. Executive Vice President, General Counsel & Corporate Secretary This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") relating to, among other things, continued development and expansion of our business, projected financial performance including sales an ...

Financial Performance - Preliminary total revenue for Q4 2025 is approximately $69.8 million, a 21% increase from $57.6 million in Q4 2024[6] - Net product sales for Q4 2025 are expected to be $65.4 million, compared to $46.5 million in Q4 2024, representing a 40% growth[6] - Rigel anticipates full-year 2026 total revenue of approximately $275 to $290 million, including net product sales of $255 to $265 million[12] - The company reported cash, cash equivalents, and short-term investments of approximately $154.6 million as of December 31, 2025, up from $77.3 million in 2024[7] - Rigel's commercial portfolio is expected to achieve full-year net product sales of $232.0 million, reflecting a 60% growth compared to 2024[8] - TAVALISSE net product sales for Q4 2025 are expected to be $45.6 million, an increase from $31.0 million in Q4 2024[6] - GAVRETO net product sales for Q4 2025 are expected to be $10.2 million, compared to $8.1 million in Q4 2024[6] - Rigel's financial performance outlook for 2026 includes increased projections, although specific figures were not disclosed[22] Clinical Development - In the Phase 1b study of R289, red blood cell transfusion independence was achieved by 33% of evaluable patients receiving doses of at least 500 mg QD[5] - Rigel plans to complete enrollment in the dose expansion phase of the Phase 1b study and select the recommended Phase 2 dose in the second half of 2026[9] - The company expects to report positive net income for the full year 2026 while funding existing and new clinical development programs[12] - The company is actively enrolling participants in the R289 clinical study, which is crucial for future product development[22] - R289 remains an investigational compound and is not yet approved by the FDA[23] Commercialization Strategy - Rigel emphasizes the importance of clinical trial outcomes in predicting real-world results for its investigational compounds[22] - The company is focused on the commercialization of TAVALISSE, GAVRETO, and REZLIDHIA in both domestic and international markets[22] - Rigel anticipates continued growth in its commercial business and expects to present data from the R289 study[22] - Risks associated with the commercialization of its products include potential adverse decisions from regulatory authorities[22] - The company does not undertake any obligation to update forward-looking statements unless required by law[22]

Revenue and Sales Performance - Total revenues for 2025 were $294.3 million, an increase of 64% compared to $179.3 million in 2024, driven by higher product sales and collaboration revenues [500]. - Net product sales of TAVALISSE reached $158.8 million in 2025, a 52% increase from $104.8 million in 2024, attributed to increased quantities sold and higher prices [502]. - REZLIDHIA net product sales were $31.0 million in 2025, up 35% from $23.0 million in 2024, primarily due to increased sales volume [502]. - GAVRETO generated $42.1 million in net product sales in 2025, compared to $17.1 million in 2024, following its commercialization in June 2024 [504]. - The company recognized $62.0 million in contract revenues from collaborations in 2025, a 80% increase from $34.4 million in 2024, largely due to non-cash revenue from collaboration with Lilly [504]. Research and Development - Research and development expenses increased to $33.3 million in 2025, up from $23.4 million in 2024, mainly due to higher clinical trial costs [510]. - Total research and development expenses for 2025 were $33.3 million, an increase from $23.4 million in 2024, with development costs rising to $29.9 million from $20.1 million [517]. - The company is advancing its dual IRAK1/4 inhibitor program in a Phase 1b study, focusing on patients with lower-risk MDS [494]. Operating Expenses - Selling, general and administrative expenses increased to $115.9 million in 2025 from $113.1 million in 2024, primarily due to increased personnel-related costs of $3.8 million [519]. - Cost of product sales for 2025 was $19.6 million, a slight increase from $18.6 million in 2024, influenced by higher royalties and amortization expenses [507]. Cash Flow and Financial Position - As of December 31, 2025, the company had approximately $155.0 million in cash, cash equivalents, and short-term investments, up from $77.3 million in 2024 [526]. - Net cash provided by operating activities in 2025 was $75.7 million, compared to $31.5 million in 2024 [527]. - The company reported a deferred income tax benefit of $245.9 million in 2025, primarily due to the release of valuation allowance on deferred tax assets [523]. Future Outlook and Funding - The company expects future revenues to be impacted by customer demand, changes in rebate programs, and potential new collaborations [506]. - The company expects to receive approximately $1.1 billion in potential future contingent payments under existing collaboration agreements, assuming all potential product candidates achieve every payment-triggering milestone [531]. - Future funding requirements will depend on various factors, including commercialization costs, clinical trial progress, and ability to generate expected revenue [535]. - The company may consider raising additional funds through public or private offerings, which could lead to shareholder dilution [534]. Debt and Obligations - The outstanding principal balance of term loans as of December 31, 2025, was $52.5 million, down from $60.0 million [533]. - As of December 31, 2025, the outstanding principal amount of the term loan was $52.5 million, with $30.0 million due within 12 months [543]. - The company has a contractual obligation related to an agreement potentially subject to cancellation fees amounting to approximately $21.5 million, with $7.3 million due in 2026 and $9.7 million due in 2027 and 2028 [538]. - The company released a $40.0 million remaining cost share liability in the second quarter of 2025 after opting not to co-fund future global development costs under the Lilly Agreement [539]. - The company has a lease agreement with Healthpeak that will expire in July 2027, with a contractual commitment of $1.2 million as of December 31, 2025, of which $0.7 million is payable within 12 months [544]. Market Risks and Investment Policy - Interest on the outstanding loan from MidCap is subject to changes in the Secured Overnight Financing Rate (SOFR), which may materially affect future interest payment obligations [547]. - The company is exposed to market risks, primarily interest rate sensitivities related to its investments and borrowings, with minimal credit risk due to high-grade securities [546]. - The company’s investment policy focuses on liquidity and capital preservation, avoiding speculative investments and derivative financial instruments [546]. - The maximum cancellation fees for contract manufacturing agreements are generally equal to the full price of the work order, depending on the timing of written notice [538]. - The company has not incurred any cancellation fees under its agreements with contract manufacturers as of December 31, 2025 [538].

Core Insights - Rigel Pharmaceuticals reported strong financial results for Q4 and full year 2025, with record net product sales and total revenues, setting a positive outlook for 2026 [1][2] Financial Performance - Total revenues for Q4 2025 were approximately $69.8 million, including net product sales of $65.4 million, a 41% increase from Q4 2024 [2][4] - For the full year 2025, total revenues reached approximately $294.3 million, with net product sales of $232.0 million, reflecting a 60% increase from 2024 [2][4] - Rigel reported a net income of $268.1 million for Q4 2025 and $367.0 million for the full year, significantly up from $14.3 million in Q4 2024 [2][4] Product Sales - Net product sales for TAVALISSE® were $45.6 million in Q4 2025, a 47% increase from Q4 2024, while GAVRETO® and REZLIDHIA® saw sales of $10.2 million and $9.6 million respectively, marking increases of 27% and 29% [2][4] - For the full year 2025, TAVALISSE® sales were $158.8 million, GAVRETO® sales were $42.1 million (up 146%), and REZLIDHIA® sales were $31.0 million (up 35%) compared to 2024 [2][4] Clinical Development - Enrollment in the Phase 1b study of R289 for lower-risk MDS is ongoing, with completion expected in the second half of 2026 [1][2] - The FDA approved a supplemental New Drug Application for GAVRETO, adding a boxed warning regarding serious infections [1][2] - Rigel presented data at the ASCO-GI symposium showing a 67% overall response rate for pralsetinib in patients with RET fusion-positive solid tumors [1][2] 2026 Outlook - Rigel anticipates total revenues of approximately $275 to $290 million for 2026, including net product sales of $255 to $265 million and positive net income [1][2]